(Journal Article): Restoration of self-tolerance is a feasible approach to control ongoing beta-cell specific autoreactivity: its relevance for treatment in established diabetes and islet transplantation
 
Chatenoud L (INSERM U25 Necker Hospital, Paris, France., chatenoud@necker.fr )
 
IN: Diabetologia 2001; 44(5):521-536
Impact Factor(s) of Diabetologia: 5.583 (2004), 5.689 (2003), 5.136 (2002), 6.299 (2001)

Fulltext:    HTML  PDF

ABSTRACT: Major progress has been made over the last 10 years in understanding the immune mechanisms underlying autoimmune Type I (insulin-dependent) diabetes mellitus. It seems that immunotherapy is the best approach for preventing and/or arresting beta cell destruction. For immunotherapeutic approaches to be clinically applicable to Type I diabetes, they cannot rely on the use of non-specific immunosuppressants. Their relative ineffectiveness over the long term and the risk of recurrence, once the drug is withdrawn, requires permanent drug treatment which augments problems of infection and drug toxicity. One solution is to selectively tackle the pathogenic immune response. Operationally, this requires establishing immunological tolerance, i.e. a state of durable antigen-specific unresponsiveness in the absence of generalised immunosuppression. This review aims to present the rationale and clinical applicability of possible immunointervention strategies in Type I diabetes aimed at restoring self-tolerance to beta cells.

TYPE OF PUBLICATION: Review

REFERENCES:

1. Castano L, Eisenbarth GS. Type-I diabetes: a chronic autoimmunedisease of human, mouse and rat. Annu Rev Immunol 1990. 8:647-679.
2. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994. 15:516-542.
3. Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 1997. 7:727-738.
4. Ellerman KE, Like AA. Susceptibility to diabetes is widely distributed in normal classIIu haplotype rats. Diabetologia 2000. 43:890-898.
5. Rossini AA, Greiner DL, Friedman HP, Mordes JP. Immunopathogenesis of diabetes mellitus. Diabetes Rev 1993. 1:43-75.
6. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y. Breeding of a non-obese, diabetic strain of mice. Exp Anim 1980. 29:1-13.
7. Yagi H, Matsumoto M, Kunimoto K, Kawaguchi J, Makino S, Harada M. Analysis of the parts of CD4+ and CD8+ T cells in autoimmune diabetes of NOD mice using transfer to NOD athymic nude mice. Eur J Immunol 1992. 22:2387-2393.
8. Bendelac A, Camaud C, Boitard C, Bach JF. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J Exp Med 1987. 166:823-832.
9. Wicker LS, Miller BJ, Mullen Y. Transfer of autoimmune diabetes mellitus with splenocytes from non-obese diabetic (NOD) mice. Diabetes 1986. 35:855-860.
10. McKeever U, Mordes JP, Greiner DL, et al. Adoptive transfer of autoimmune diabetes and thyroiditis to athymic rats. Proc Natl Acad Sci USA 1990. 87:7618-7622.
11. Daniel D, Gill RG, Schloot N, Wegmann D. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur J Immunol 1995. 25:1056-1062.
12. Wegmann DR, Gill RG, Norbury-Glaser M, Schloot N, Daniei D. Analysis of the spontaneous T cell response to insulin in NOD mice. J Autoimmun 1994. 7:833-843.
13. Wegmann DR, Norbury-Glaser M, Daniel D. Insulin-specific T cells are apredominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol 1994. 24:1853-1857.
14. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA 1996. 93:956-960.
15. Atkinson MA, MacLaren NK, Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990. 39:933-937.
16. Harrison LC, Honeyman MC, Trembleau S, et al. A peptide-binding motif for I-A(g7), the class II major histocompatibility complex (MHC) molecule of NOD and Biozzi AB/H mice. J Exp Med 1997. 185:1013-1021.
17. French MB, Allison J, Cram DS, et al. Transgenic expression of mouse proinsulin Ir prevents diabetes in nonobese diabetic mice. Diabetes 1997. 46:34-39.
18. Baekkeskov S, Aanstoot HJ, Christgau S, et al. Identification of the 64 K auto antigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990. 347:151-156.
19. Honeyman MC, Cram DS, Harrison LC. Glutamic acid decarboxylase 67-reactive T cells: a marker of insulin-dependent diabetes. J Exp Med 1993. 177:535-540.
20. Panina-Bordignon P, Lang R, Van Endert PM, et al. Cytotoxic T cells speeific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med 1995. 181:1923-1927.
21. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993. 366:72-75.
22. Trembleau S, Penna G, Gregori S, Gately MK, Adorini L. Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes. Eur J Immunol 1997. 27:2330-2339.
23. Hawkes CJ, Wasmeier C, Christie MR, Hutton JC. Identification of the 37-kDa antigen in IDDM as a tyrosine phosphatase-like protein (phogrin) related to IA-2. Diabetes 1996. 45:1187-1192.
24. Dotta F, Dionisi S, Viglietta V, et al. T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus. Eur J Endocrinol 1999. 141:272-278.
25. Hawa M, Rowe R, Lan MS, et al. Value of antibodies to islet protein tyrosine phosphatase-like molecule in predicting Type 1 diabetes. Diabetes 1997. 46:1270-1275.
26. Lampasona V, Bearzatto M, Genovese S, Bosi E, Ferrari M, Bonifacio E. Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen. J Immunol 1996. 57:2707-2711.
27. Elias D, Markovits D, ReshefT, Van Der Zee R, Cohen IR. Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOP/Lt) mouse by a 65-kDa heat shock protein. Proc Natl Acad Sci USA 1990. 87:1576-1580.
28. Elias D, Reshef T, Birk OS, Van Der Zee R, Walker MD, Cohen IR. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci USA 1991. 88:3088-3091.
29. Elias D, Cohen IR. Peptide therapy for diabetes in NOD mice. Lancet 1994. 343:704-706.
30. Birk OS, Douek DC, Elias D, et al. Apart of hsp60 in autoimmune diabetes: analysis in a transgenic model. Proc Natl Acad Sei USA 1996. 93:1032-1037.
31. Elias D, Meilin A, Ablamunits V, et al. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes 1997. 46:758-764.
32. Moustakas AK, Routsias J, Papadopoulos GK. Modelling of the MHC II allele I-A(g7) of NOD mouse: pH-dependent changes in specificity at pockets 9 and 6 explain several of the unique properties of this molecule. Diabetologia 2000. 43:609-624.
33. Xu XJ, Gearon C, Stevens E, Vergani D, Baum H, Peakman M. Spontaneous T-cell proliferation in the non-obese diabetic mouse to a peptide from the unique class II MHC molecule, I-Ag7, which is also protective against the development of autoimmune diabetes. Diabetologia 1999. 42:560-565.
34. Kanagawa O, Martin SM, Vaupel BA, Carrasco-Marin E, Unanue ER. Autoreactivity of T cells from non-obese diabetic mice: an I-Ag7-dependent reaction. Proc Nat Acad Sci USA 1998. 95:1721-1724.
35. Feutren G, Papoz L, Assan R, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986. ii:119-124.
36. The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988. 37:1574-1582.
37. Schwartz RH. Immunological tolerance. In: Paul WE (eds) Fundamental Immunology 1993. Raven Press, New York, pp 677-731.
38. Vafiadis P, Bennett ST, Todd JA, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 1997. 15:289-292.
39. Hanahan D. Peripheral-antigen-expressing cells in thymic medulla: factors in self-tolerance and autoimmunity. Curr Opin Immunol 1998. 10:656-662.
40. Lohmann T, Leslie RDG, Londei M. T cell clones to epitopes of glutamic acid decarboxylase 65 raised from normal subjects and patients with insulin-dependent diabetes. J Autoimmun 1996. 9:385-389.
41. Ohashi PS, Oehen S, Buerki K, et al. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991. 65:305-317.
42. Mason D, Powrie F. Control of immune pathology by regulatory T cells. Curr Opin Immunol 1998. 10:649-655.
43. Shevach EM. Regulatory Tcells in autoimmmunity. Annu Rev Immunol 2000. 18:423-449.
44. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000. 101:455-458.
45. Boitard C, Yasunami R, Dardenne M, Bach JF. T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice. J Exp Med 1989. 169:1669-1680.
46. Hutchings PR, Cooke A. The transfer of autoimmune diabetes in NOD mice can be inhibited or accelerated by distinct cell populations present in normal splenocytes taken from young males. J Autoimmun 1990. 3:175-185.
47. Yasunami R, Debray-Sachs M, Bach JF. Ontogeny of regulatory and effector T-cells in autoimmune NOD mice. In: Shafrir E (eds) Frontiers in diabetes research. Lessons from animal diabetes, 1990. Vol. 3. Smith-Gordon, London, pp 88-93.
48. Sempe P, Richard MF, Bach JF, Boitard C. Evidence of CD4+ regulatory T cells in the non-obese diabetic male mouse. Diabetologia 1994. 37:337-343.
49. Askenase PW, Hayden BJ, Gershon RK. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J Exp Med 1975. 141:697-702.
50. Minagawa H, Takenaka A, ltoyama Y, Mori R. Experimental allergic encephalomyelitis in the Lewis rat. A model of predictable relapse by cyclophosphamide. J Neurol Sci 1987. 78:225-235.
51. Miyazaki C, Nakamura T, Kaneko K, Mori R, Shibasaki H. Reinduction of experimental allergic encephalomyelitis in convalescent Lewis rats with cyclophosphamide. J Neurol Sci 1985. 67:277-284.
52. McKenna RM, Carter BG, Sehon AH. Studies on the mechanism of suppression of experimental allergic encephalomyelitis induced by myelin basic protein-cell conjugates. Cell Immunol 1984. 88:251-259.
53. Kardys E, Hashim GA. Experimental allergic encephalomyelitis in Lewis rats: immunoregulation of disease by a single amino acid substitution in the disease-inducing determinant. J Immunol 1981. 127:862-866.
54. Charlton B, Bacelj A, Slattery RM, Mandel TE. Cyclophosphamide-induced diabetes in NOD/WEHI mice. Evidence for suppression in spontaneous autoimmune diabetes mellitus. Diabetes 1989. 38:441-447.
55. Dardenne M, Lepault F, Bendelac A, Bach JF. Acceleration of the onset of diabetes in NOD mice by thymectomy at weaning. Eur J Immunol 1989. 19:889-895.
56. Gombert JM, HerbeIin A, Tancrede-Bohin E, Dy M, Carnaud C, Bach JF. Early quantitative and functional deficiency of NK1(+)-like thymocytes in the NOD mouse. Eur J Immunol 1996. 26:2989-2998.
57. Baxter AG, Kinder SJ, Hammond KJL, Scollay R, Godfrey DI. Association between alpha beta TCR(+)CD4(-)CD8(-) T-cell deficiency and IDDM in NOD/Lt mice. Diabetes 1997. 46:572-582.
58. Rapoport MJ, Jaramillo A, Zipris D, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993. 178:87-99.
59. Pennline KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994. 71:169-175.
60. Mueller R, Krahl T, Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996. 184:1093-1099.
61. Jackson R, Rassi N, Crump T, Haynes B, Eisenbarth GS. The BB diabetic rat. Profound T-cell Iymphocytopenia. Diabetes 1981. 30:887-889.
62. Greiner DL, Handler ES, Nakano K, Mordes JP, Rossini AA. Absence of the RT-6 T cell subset in diabetes-prone BB/W rats. J Immunol 1986. 136:148-151.
63. Greiner DL, Mordes JP, Handler ES, Angelillo M, Nakamura N, Rossini AA. Depletion of RT6.1+ T lymphocytes in duces diabetes in resistant biobreeding/ Worcester (BB/W) rats. J Exp Med 1987. 166:461-475.
64. Rossini AA, Mordes JP, Greiner DL, Nakano K, Appel MC, Handler ES. Spleen cell transfusion in the Bio-Breeding/Worcester rat. Prevention of diabetes, major histocompatibility complex restriction, and long-term persistence of transfused cells. J Clin Invest 1986. 77:1399-1401.
65. Fowell D, Mason D. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential. J Exp Med 1993. 177:627-636.
66. Bowman MA, Leiter EH, Atkinson MA. Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. Immunol Today 1994. 15:115-120.
67. Kaufman DL, Clare-Salzler M, Tian J, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993. 366:69-72.
68. Elliott JF, Qin HY, Bhatti S, et al. Immunization with the larger isoform of mouse glutamic acid decarboxylase (GAD67) prevents autoimmune diabetes in NOD mice. Diabetes 1994. 43:1494-1499.
69. Gotfredsen CF, Buschard K, Frandsen EK. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 1985. 28:933-935.
70. Bertrand S, de Paepe M, Vigeant C, Yale JF. Prevention of adoptive transfer in BB rats by prophylactic insulin treatment. Diabetes 1992. 41:1273-1277.
71. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 1991. 88:10252-10256.
72. Bergerot I, Ploix C, Petersen J, et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA 1997. 94:4610-4614.
73. Muir A, Peck A, Clare-Salzler M, et al. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. J Clin Invest 1995. 95:628-634.
74. Karounos DG, Bryson JS, Cohen DA. Metabolically inactive insulin analog prevents Type I diabetes in pre-diabetic NOD mice. J Clin Invest 1997. 100:1344-1348.
75. Hanninen A, Harrison LC. Gamma delta T cells as mediators of mucosal tolerance: the autoimmune diabetes model. Immunol Rev 2000. 173:109-119.
76. Harrison LC, Dempseycollier M, Kramer DR, Takahashi K. Aerosol insulin induces regulatory CD8 gammadelta T cells that prevent murine insulin-dependent diabetes. J Exp Med 1996. 184:2167-2174.
77. Tian J, Lehmann PV, Kaufman DL. Determinant spreading of T helper cell 2 (Th2) responses to pancreatic islet autoantigens. J Exp Med 1997. 186:2039-2043.
78. AI-Sabbagh A, Miller A, Santos LM, Weiner HL. Antigen-driven tissue-specific suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse. Eur J Immunol 1994. 24:2104-2109.
79. Tian JD, Claresalzler M, Herschenfeld A, et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nature Med 1996. 2:1348-1353.
80. Tian JD, Atkinson MA, Claresalzler M, et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996. 183:1561-1567.
81. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975. 256:495-497.
82. Kung P, Goldstein G, Reinherz EL, Schlossman SF. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 1979. 206:347-349.
83. Jonker M, Goldstein G, Balner H. Effects of in vivo administration of monoclonal antibodies specific for human Teell subpopulations on the immune system in a rhesus monkey model. Transplantation 1983. 35:521-526.
84. Jonker M, Malissen B, Mawas C. The effect of in vivo application of monoclonal antibodies specific for human cytotoxic T cells in rhesus monkeys. Transplantation 1983. 35:374-378.
85. Jonker M, Neuhaus P, Zureher C, Fueello A, Goldstein G. OKT4 and OKT4A antibody treatment as immunosuppression for kidney transplantation in rhesus monkeys. Transplantation 1985. 39:247-253.
86. Nieolls MR, Aversa GG, Pearee NW, et al. Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody. Transplantation 1993. 55:459-468.
87. Qin S, Cobbold SP, Pope H, et al. "Infectious" transplantation toleranee. Science 1993. 259:974-977.
88. Cobbold SP, Adams E, Marshall SE, Davies JD, Waldmann H. Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol Rev 1996. 149:5-33.
89. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996. 381:434-438.
90. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999. 5:686-693.
91. Bushell A, Niimi M, Morris PJ, Wood KJ. Evidence for immune regulation in the induction of transplantation tolerance: a conditional but limited part for IL-4. J Immunol 1999. 162:1359-1366.
92. Niimi M, Pearson TC, Larsen CP, et al. The part of the CD40 pathway in alloantigen-induced hyporesponsiveness in vivo. J Immunol 1998. 161:5331-5337.
93. Thomas JM, Carver FM, Foil MB, Hall WR, Adams C, Fahrenbrueh GB. Renal allograft tolerance induced with ATG and donor bone marrow in outbred rhesus monkeys. Transplantation 1983. 36:104-106.
94. Thomas J, Carver M, Cunningham P, Park K, Gonder J, Thomas F. Promotion of incompatible allograft acceptance in rhesus monkeys given posttransplant antithymocyte globulin and donor bone marrow. I. In vivo parameters and immunohistologic evidence suggesting microchimerism. Transplantation 1987. 43:332-338.
95. Thomas JM, Carver FM, Cunningham PR, Olson LC, Thomas FT. Kidney allograft tolerance in primates without chronic immunosuppression-the part of veto cells. Transplantation 1991. 51:198-207.
96. Thomas J, Alqaisi M, Cunningham P, et al. The development of a posttransplant TU treatment strategy that promotes organ allograft acceptance without chronic immunosuppression. Transplantation 1992. 53:247-258.
97. Thomas FT, Ricordi C, Contreras JL, et al. Reversal of naturally occurring diabetes in primates by unmodified islet xenografts without chronic immunosuppression. Transplantation 1999. 67: 846-854
98. Hamawy MM, Kneehtle SJ. Strategies for toleranee induction in nonhuman primates. Curr Opin Immunol 1998. 10:513-517.
99. Thomas JM, Neville DM, Contreras JL, et al. Pre-clinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts. Transplantation 1997. 64:124-135.
100. Cobbold S, Waldmann H. Infectious tolerance. Curr Opin Immunol 1998. 10:518-524.
101. Hayward AR, Shreiber M. Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes. J Immunol 1989. 143:1555-1559.
102. Boitard C, Bendelac A, Richard MF, Carnaud C, Bach JF. Prevention of diabetes in nonobese diabetic mice by anti-I-A monoclonal antibodies: transfer of protection by splenic T cells. Proc Natl Acad Sci USA 1988. 85:9719-9723.
103. Shizuru JA, Taylor-Edwards C, Banks BA, Gregory AK, Fathman CG. Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science 1988. 240:659-662.
104. Hutchings P, O'Reilly L, Parish NM, Waldmann H, Cooke A. The use of a non-depleting anti-CD4 monoclonal antibody to reestablish tolerance to beta cells in NOD mice. Eur J Immunol 1992. 22:1913-1918.
105. Charlton B, Bacelj A, Mandel TE. Administration of silica particles or anti-Lyt2 antibody prevents beta-ce1l destruction in NOD mice given cyclophosphamide. Diabetes 1988. 37:930-935.
106. Sempe P, Bedossa P, Richard MF, Villa MC, Bach JF, Boitard C. Anti-alpha/beta T eell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice. Eur J Immunol 1991. 21:1163-1169.
107. Balasa B, Krahl T, Patstone G, et al. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997. 159:4620-4627.
108. Ikehara S, Ohtsuki H, Good RA, et al. Prevention of Type I diabetes in nonobese diabetic mice by allogenic bone marrow transplantation. Proc Natl Acad Sci USA 1985. 82:7743-7747.
109. Serreze DV, Chapman HO, Varnum OS, et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: Analysis of a new 'speed congenic' stock of NOD.Ig mu(null) mice. J Exp Med 1996. 184:2049-2053.
110. Noorchashm H, Lieu YK, Noorchashm N, et al. I-ag7-mediated antigen presentation by b lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. J Immunol 1999. 163:743-750.
111. Posseit AM, Barker CF, Tomaszewski JE, Markmann JF, Choti MA, Naji A. Induction of donor-specific unresponsiveness by intrathymic islet transplantation. Science 1990. 249:1293-1295.
112. Campos L, Posseit AM, Deli BC, et al. The failure of intrathymic transplantation of nonimmunogenic islet allografts to promote induction of donor-specific unresponsiveness. Transplantation 1994. 57:950-953.
113. Koevary SB, BIomberg M. Prevention of diabetes in BB/Wor rats by intrathymic islet injection. J Clin Invest 1992. 89:512-516.
114. Charlton B, Taylor Edwards C, Tisch R, Fathman CG. Prevention of diabetes and insulitis by neonatal intrathymic islet administration in NOD mice. J Autoimmun 1994. 7:549-560.
115. Gerling IC, Serreze DV, Christianson SW, Leiter EH. Intrathymic islet cell transplantation reduces beta-cell autoimmunity and prevents diabetes in NOD/Lt mice. Diabetes 1992. 41:1672-1676.
116. Posseit AM, Barker CF, Friedman AL, Naji A. Prevention of autoimmune diabetes in the BB rat by intra-thymic islet transplantation at birth. Science 1992. 256:1321-1324.
117. Wekerle T, Kurtz J, Ho H, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000. 6:464-469.
118. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stern cells from related donars with one fully mismatched HLA haplotype N Engl J Med 1998. 339:1186-1193.
119. Reisner Y, Martelli MF. Stern cell escalation enables HLA-disparate haematopoietic transplants in leukaemia patients. Immunol Today 1999. 20:343-347.
120. Levy MM, Ketchum RJ, Park DH, et al. Engraftment and function of intrathymic pancreatic is1et autografts in dogs. Transplant Proc 1995. 27:607-608.
121. Merhav H, Ye Y, Niekrasz M, et al. Failure of intra-thymic inoculation of donor-specific splenocytes to prolong cardiac or renal allograft survival in dogs. Transpl Immunol 1995. 3:39-44.
122. Allen MD, Weyhrich J, Gaur L, et al. Prolonged allogeneic and xenogeneic microchimerism in unmatched primates without immunosuppression by intrathymic implantation of CD34+ donor marrow cells. Cell Immunol 1997. 181:127-138.
123. Sreenan S, Pick AJ, Levisetti M, Baldwin AC, Pugh W, Polonsky KS. Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes 1999. 48:989-996.
124. StrandeIl E, Eizirik DL, Sandler S. Reversal of beta-cell suppression in vitro in pancreatic islets isolated from nonobese diabetic mice during the phase preceding insulin-dependent diabetes mellitus. J Clin Invest 1990. 85:1944-1950.
125. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994. 91:123-127.
126. Maki T, Ichikawa T, Blanco R, Porter J. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc Natl Acad Sci USA 1992. 89:3434-3438.
127. Boitard C, Chatenoud L, Debray-Sachs M. In vitro inhibition of pancreatic B cell function by lymphocytes from diabetics with associated autoimmune diseases: a T cell phenomenon. J Immunol 1982. 129:2529-2531.
128. Kanatsuna T, Baekkeskov S, Lernmark A, Ludvigsson J. Immunoglobulin from insulin-dependent diabetic children inhibits glucose-induced insulin release. Diabetes 1983. 32:520-524.
129. Srikanta S, Ganda OP, Eisenbarth GS, Soeldner JS. Islet-cell antibodies and beta-cell function in monozygotic trip lets and twins initially discordant for type I diabetes mellitus. N Engl J Med 1983. 308:322-325.
130. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 1989. 320:550-554.
131. Bougneres PF, Carel JC, Castano L, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988. 318:663-670.
132. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy,in patients with autoimmune diseases. (International kidney biopsy registry of cyclosporine in autoimmune diseases). N Engl J Med 1992. 326:1654-1660.
133. Feldt-Rasmussen B, Jensen T, Dieperink H, et al. Nephrotoxicity of cyclosporin A in patients with newly diagnosed Type 1 diabetes mellitus. Diabet Med 1990. 7:429-433.
134. Parving HH, Tarnow L, Nielsen FS, et al. Cyclosporine nephrotoxicity in Type 1 diabetic patients. A 7-year follow-up study. Diabetes Care 1999. 22:478-483.
135. Mihatsch MJ, Antonovych T, Bohman SO, et al. Cyclosporin A nephropathy: standardization of the evaluation of kidney biopsies. Clin Nephrol 1994. 41:23-32.
136. Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of Type I diabetes. Lancet 1993. 341:927-928.
137. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996. 45:622-626.
138. Blanas E, Carbone FR, Allison J, Miller JF, Heath WR. Induction of autoimmune diabetes by oral administration of autoantigen. Science 1996. 274:1707-1709.
139. Chatenoud L, Baudrihaye MF, Kreis H, Goldstein G, Schindler J, Bach JF. Human in vivo anti genie modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol 1982. 12:979-982.
140. Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, Bach JF. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 1986. 137:830-838.
141. Hirsch R, Eckhaus M, Auchincloss H JR, Sachs DH, Bluestone JA. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J Immunol 1988. 140:3766-3772.
142. Cosimi AB, Colvin RB, Burton RC, et al. Use of monoclonal antibodies to T-cell subsets far immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981. 305:308-314.
143. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985. 313:337-342.
144. Debure A, Chkoff N, Chatenoud L, et al. One-month prophylactic use of OKT3 in cadaver kidney transplant recipients. Transplantation 1988. 45:546-553.
145. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997. 158:2947-2954.
146. Leo 0, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 1987. 841374-1378.
147. Chatenoud L, Legendre C, Ferran C, Bach JF, Kreis H. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome-dosage and kinetics prerequisites. Transplantation 1991. 51:334-338.
148. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989. 47:606-608.
149. Eason lD, Cosimi AB. Biologic immunosuppressive agents. In: Ginns LC, Cosimi AB, Morris Pl (eds) Transplantation, Blackwell Science 1999, Maiden pp 196-224.
150. Hirsch R, Gress RE, Pluznik DH, Eckhaus M, Bluestone JA. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. 1 Immunol 1989. 142:737-743.
151. Ferran C, Sheehan K, Dy M, et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol 1990. 20:509-515.
152. Alegre M, Vandenabeele P, Flamand V, et al. Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: part of tumor necrosis factor. Eur J Immunol 1990. 20:707-710.
153. Durez P, Abramowicz D, Gerard C, et al. In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A. J Exp Med 1993. 177:551-555.
154. Yoshimoto T, Paul WE. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 1994. 179:1285-1295.
155. Flamand V, Abramowicz D, Goldman M, et al. Anti-CD3 antibodies induce T cells from unprimed animals to secrete IL-4 both in vitro and in vivo. J Immunol 1990. 144:2875-2882.
156. Sawchuk SS, Gates R, Hirsch R. Contrasting in vivo effects on T helper cell functions induced by mitogenic (intact) versus nonmitogenic (F(ab')2) anti-CD3 monoclonal antibody. Transplantation 1995. 60:1331-1337.
157. Van Wauwe JP, de Mey JR, Goossens JG. OKT3: a monoclonal anti-human T Iymphocyte antibody with potent mitogenic properties. J Immunol 1980. 124:2708-2713.
158. Hirsch R, Bluestone JA, de Nenno L, Gress RE. Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 1990. 49:1117-1123.
159. Van Lier RA, Boot JH, de Groot ER, Aarden LA. Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain iso-type in monocyte-dependent systems. Eur J Immunol 1987. 17:1599-1604.
160. Parlevliet KJ, Ten Berge IJ, Yong SL, Surachno J, Wilmink JM, Schellekens PT. In vivo effects of IgA and IgG2 a anti-CD3 isoType switch variants. J Clin Invest 1994. 93:2519-2525.
161. Hirsch R, Archibald 1, Gress RE. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction. J Immunol 1991. 147:2088-2093.
162. Hughes C, Wolos JA, Giannini EH, Hirsch R. Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody. J Immunol 1994. 153:3319-3325.
163. Herold KC, Bluestone JA, Montag AG, et al. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992. 41:385-391.
164. Johnson BD, McCabe C, Hanke CA, Truitt RL. Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-Ieukemia reactivity after MHC-matched bone marrow transplantation. J Immunol 1995. 154:5542-5554.
165. Woodle ES, Xu D, Zivin RA, et al. Phase I trial of a humanized, Fe receptor nonbinding OKT3 antibody, hu-OKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999. 68:608-616.
166. Friend PJ, Haie G, Chatenoud L, et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 1999. 68:1632-1637.
167. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988. 332:323-327.
168. Bolt S, Routledge E, Lloyd I, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993. 23:403-411.
169. Alegre ML, Peterson LJ, Xu D, et al. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994. 57:1537-1543.
170. Routledge EG, Falconer ME, Pope H, Lloyd IS, Waldmann H. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Transplantation 1995. 60:847-853.
171. Auchincloss H, Shaffer D. Pancreas Transplantation. In: Ginns LC, Cosimi AB, Morris Pl (eds) Transplantation, Blackwell Science Inc. 1999, Maiden, pp 395-421.
172. Keymeulen B, Ling Z, Gorus FK, et al. Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipients characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft. Diabetologia 1998. 41:452-459.
173. Alejandro R, Lehmann R, Ricordi C, et al. Long-term function (6 years) of islet allografts in Type 1 diabetes. Diabetes 1997. 46:1983-1989.
174. Kenyon NS, Alejandro R, Mintz DH, Ricordi C. Islet cell transplantation: beyond the paradigms. Diabetes Metab Rev 1996. 12:361-372.
175. Inverardi L, Ricordi C. Transplantation of pancreas and islets of Langerhans: a review of progress. Immunol Today 1996. 17:7-9.
176. Naji A, Silvers WK, Bellgrau D, Barker CF. Spontaneous diabetes in rats: destruction of islets is prevented by immunological tolerance. Science 1981. 213:1390-1392.
177. Uchikoshi F, Yang ZD, Rostami S, et al. Prevention of autoimmune recurrence and rejection by adenovirusmediated CTLA4Ig gene transfer to the pancreatic graft in BB rat. Diabetes 1999. 48:652-657.
178. Hegre OD, Enriquez Al, Ketchum RJ, Weinhaus AJ, Serie JR. Islet transplantation in spontaneously diabetic BB/Wor rats. Diabetes 1989. 38:1148-1154.
179. Casteels K, Waer M, Laureys J, et al. Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine. Transplantation 1998. 65:1225-1232.
180. Wang Y, Pontesilli 0, Gill RG, La Rosa FG, Lafferty KJ. The part of CD4+ and CD8+ T cells in the destruction of islet grafts by spontaneously diabetic mice. Proc Natl Acad Sci USA 1991. 88:527-531.
181. Tyden G, Reinholt FP, Sundkvist G, Bolinder J. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med 1996. 335:860-863.
182. Sibley RK, Sutherland DE, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest 1985. 53:132-144.
183. Eisenbarth GS, Stegall M. Islet and pancreatic transplantation - autoimmunity and alloimmunity. N Engl J Med 1996. 335:888-890.
184. Waldmann H, Cobbold S. How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annu Rev Immunol 1998. 16:619-644.
185. Davies JD, Leong LY, Mellor A, Cobbold SP, Waldmann H. T cell suppression in transplantation tolerance through linked recognition. J Immunol 1996. 156:3602-3607.
186. Roep BO, Stobbe I, Duinkerken G, et al. Auto- and alloimmune reactivity to human islet allografts transplanted into Type 1 diabetic patients. Diabetes 1999. 48:484-490.
187. Monaco AP, Wood ML, Russell PS. Studies on heterologous antilymphocyte serum in mice. III. Immunological tolerance and chimerism produced across the H2-locus with adult thymectomy and antilymphocyte serum. Ann NY Acad Sci 1966. 129:190-209.
188. Wood ML, Monaco AP, Gozzo JJ, Liegeois A. Use of homozygous allogeneic bone marrow for induction of tolerance with antilymphocyte serum: dose and timing. Transplant Proc 1971. 3:676-679.
189. Wang B, Gonzalez A, Benoist C, Mathis D. The part of CD8(+) T cells in the initiation of insulin-dependent diabetes mellitus. Eur J Immunol 1996. 26:1762-1769.
190. Arreaza GA, Cameron MJ, Jaramillo A, et al. Neonatal activation of CD28 signaling overcomes T cell anergy and prevents autoimmune diabetes by an IL-4-dependent mechanism. J Clin Invest 1997. 100:2243-2253
191. Kelley VE, Gaulton GN, Hattori M, Ikegami H, Eisenbarth G, Strom TB. Anti-interleukin 2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis. J Immunol 1988. 140:59-61.
192. Campbell IL, KayTW, Oxbrow L, Harrison LC. Essential part for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest 1991. 87:739-742.
193. Debray-Sachs M, Carnaud C, Boitard C, et al. Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. J Autoimmun 1991. 4:237-248.
194. Hasegawa Y, Yokono K, Taki T, et al. Prevention of autoimmune insulin-dependent diabetes in non-obese diabetic mice by anti-LFA-l and anti-ICAM-l mAb. Int Immunol 1994. 6:831-838.
195. Moriyama H, Yokono K, Amano K, et al. Induction of tolerance in murine autoimmune diabetes by transient blockade of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 pathway. J Immunol 1996. 157:3737-3743.
196. Yang XD, Karin N, Tisch R, Steinman L, McDevitt HO. Inhibition of insulitis and prevention of diabetes in nonobese diabetic mice by blocking L-selectin and very late antigen 4 adhesion receptors. Proc Natl Acad Sci USA 1993. 90:10494-10498.
197. Like AA, Rossini AA, Guberski DL, Appel MC, Williams RM. Spontaneous diabetes mellitus: reversal and prevention in the BB/W rat with antiserum to rat lymphocytes. Science 1979. 206:1421-1423.
198. Hahn HJ, Lucke S, Kloting I, Volk HD, Baehr RY, Diamantstein T. Curing BB rats of freshly manifested diabetes by short-term treatment with a combination of a monoclonal anti-interleukin 2 receptor antibody and a subtherapeutic dose of cyclosporin A. Eur J Immunol 1987. 17:1075-1078.
199. Nicoletti F, Meroni PL, Landolfo S, et al. Prevention of diabetes in BB/Wor rats treated with monoclonal antibodies to interferon-gamma. Lancet 1990. 336:319
200. Boitard C, Michie S; Serrurier P, Butcher GW, Larkins AP, McDevitt HO. In vivo prevention of thyroid and pancreatic autoimmunity in the BB rat by antibody to class II major histocompatibility complex gene products. Proc Natl Acad Sci USA 1985. 82:6627-6631.